Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced Research and Development Authority (BARDA) Innovation Symposium on November 20, 2025, in Washington, D.C. The event... Read More

Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U.S. government funding proposals HALIFAX, Nova Scotia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development... Read More

HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today (the “ Meeting ”). Based on the proxies received and the vote conducted at the Meeting,... Read More

Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus,... Read More

Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening government and biodefense partnerships HALIFAX, Nova Scotia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug... Read More

Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a new publication in... Read More

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today... Read More

HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, in response to the notice received from Aditxt Inc. (“ Aditxt ”) on May 17, 2025, the Company has delivered formal notice to Aditxt to terminate the... Read More

HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“ Aditxt ”) has delivered notice (the “ Termination Notice ”) purporting to terminate the arrangement agreement dated April 1, 2024... Read More

HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a potentially lethal bacterial infection. Dr. Carl Gelhaus, Ph.D., Director of... Read More

New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book HALIFAX, Nova Scotia, April 28, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or "Appili"), a biopharmaceutical company focused on... Read More

Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its... Read More

Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for... Read More

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission Further strengthened government partnerships, reinforcing Appili’s position as a key player in biodefense and infectious disease solutions. HALIFAX, Nova Scotia, Feb. 14, 2025 (GLOBE NEWSWIRE) -... Read More

Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce receipt of the final order of the Ontario Superior Court... Read More

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission HALIFAX, Nova Scotia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink:... Read More

HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its special meeting of shareholders held earlier today (the “Meeting”). Shareholders of the Company (the “Shareholders”), overwhelmingly voted in... Read More

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug... Read More

ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentation scheduled for 3:15 pm ET on October 17, 2024 HALIFAX, Nova Scotia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on... Read More

HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders” issued on October 10, 2024 (the “Initial Press Release”). The Initial Press Release, incorrectly stated... Read More

Your vote is important no matter how many votes you hold. Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures,... Read More

HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today. Based on the proxies received and the vote conducted at the meeting, all tabled... Read More

HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a third amending agreement (the “ Amending Agreement ”) among the Company, Aditxt, Inc. (“ Aditxt ”) and Adivir, Inc. (“ Adivir ” and together... Read More

Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs ATI-1701 funding commitments from U.S. Air Force Academy and interactions with the U.S. Food and Drug Administration, confirming the development pathway through IND submission U.S. Food and Drug Administration meeting request submitted to discuss ATI-1801 registration... Read More

HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a second amending agreement (the “ Amending Agreement ”) among the Company, Aditxt, Inc. (“ Aditxt ”) and Adivir, Inc. (“ Adivir ” and... Read More

HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into an amending agreement (the “ Amending Agreement ”) among the Company, Aditxt, Inc. (“ Aditxt ”) and Adivir, Inc. (“ Adivir ” and together with... Read More

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development plans HALIFAX, Nova Scotia, June 25, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a... Read More

HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000 (the “ Bridge Loan ”) from Bloom Burton & Co. Inc. (the “ Lender ”). The Bridge Loan... Read More

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today... Read More

HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with... Read More

FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development plans HALIFAX, Nova Scotia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or... Read More

Patent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies HALIFAX, Nova Scotia / Dec 15, 2023 / Business Wire / Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced... Read More

FDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701, bringing the total program funding awarded to US$14 million Appili Therapeutics Appoints Seasoned Biopharma Executive Mr. Prakash Gowd to its Board of Directors HALIFAX, Nova Scotia / Nov 13, 2023 / Business Wire / Appili Therapeutics Inc.... Read More

Additional US$6.6 million funding commitment for ATI-1701 brings the total program funding awarded to approximately US$14 million These funds along with other potential funding sources, are anticipated to continue to advance the ATI-1701 program toward an IND submission to the FDA in 2024 The company also announces a change to it’s Board of Directors HALIFAX, Nova Scotia / Oct 25, 2023 / Business Wire / Appili Therapeutics... Read More

HALIFAX, Nova Scotia / Sep 27, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual meeting of shareholders held earlier today. Results of Annual Meeting Based on the proxies received and the vote conducted at the meeting, all tabled... Read More

Recently announced Funding Commitment from U.S. Air Force is expected to advance ATI-1701 Biodefense Vaccine Candidate to IND HALIFAX, Nova Scotia / Sep 27, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical... Read More

FDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the U.S. Patent coverage provides drug market exclusivity through at least 2039 HALIFAX, Nova Scotia / Sep 25, 2023 / Business Wire / Appili Therapeutics Inc. ( TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a... Read More

FDA established a PDUFA action date for ATI-1501 of September 23, 2023 Government funding committed to enable Appili to advance its biodefense vaccine candidate ATI-1701 towards an IND HALIFAX, Nova Scotia / Aug 11, 2023 / Business Wire / Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today... Read More

HALIFAX, Nova Scotia / Jun 29, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that it has entered into a definitive agreement with respect to an unsecured C$300,000 bridge loan (the “Bridge Loan”) from Bloom Burton & Co. Inc. (the “Lender”). As... Read More

HALIFAX, Nova Scotia / Jun 23, 2023 / Business Wire / Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), announced today a correction to its press release entitled “Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results” which was issued on June 23, 2023 (the “Initial Press Release”). The Initial Press Release, under the heading entitled “ ATI-1501, with Patent Coverage... Read More

Executed US$7.3M initial contract with U.S. Air Force Academy for ATI-1701 Upcoming PDUFA date of September 23, 2023 for ATI-1501 HALIFAX, Nova Scotia / Jun 23, 2023 / Business Wire / Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for... Read More

Upcoming PDUFA date of September 23, 2023 HALIFAX, Nova Scotia / May 24, 2023 / Business Wire / Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1501 under the U.S. Application No.... Read More

Funding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND HALIFAX, Nova Scotia / May 08, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the Company has executed the initial contract with the U.S. Air Force Academy (USAFA) for... Read More

Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine Congress in Washington, D.C. HALIFAX, Nova Scotia / Apr 03, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug... Read More

HALIFAX, Nova Scotia / Mar 20, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement (the “ Amended Loan Agreement ”) with Long Zone Holdings Inc. (“ LZH ”), amending and restating the... Read More

HALIFAX, Nova Scotia / Feb 14, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022. “Over the past couple of months, it has been an immense honor... Read More

HALIFAX, Nova Scotia / Feb 08, 2023 / Business Wire / Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today, with its partner Saptalis Pharmaceuticals LLC (“Saptalis”), announced that the Food and Drug Administration (“FDA”) accepted the ATI-1501 New Drug Application (“NDA”). ATI-1501 is Appili’s liquid oral... Read More

Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran,... Read More

Anticipated new patent strengthens ATI-1501’s potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has... Read More